ECSP24038829A - Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno - Google Patents

Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Info

Publication number
ECSP24038829A
ECSP24038829A ECSENADI202438829A ECDI202438829A ECSP24038829A EC SP24038829 A ECSP24038829 A EC SP24038829A EC SENADI202438829 A ECSENADI202438829 A EC SENADI202438829A EC DI202438829 A ECDI202438829 A EC DI202438829A EC SP24038829 A ECSP24038829 A EC SP24038829A
Authority
EC
Ecuador
Prior art keywords
disorder
disease
treatment
naphthyridinone derivatives
naphthyridinone
Prior art date
Application number
ECSENADI202438829A
Other languages
English (en)
Inventor
Atwood Kim Cheung
Yu Gai
Donglei Liu
Xingjuan Chang
Stefan Peukert
Heng Ge
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP24038829A publication Critical patent/ECSP24038829A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un compuesto de la fórmula (I) o una de sus sales farmacéuticamente aceptables, donde A, R1 y R3 son como se describen en el presente documento, así como composiciones y métodos de uso de dichos compuestos.
ECSENADI202438829A 2021-11-23 2024-05-21 Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno ECSP24038829A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163282492P 2021-11-23 2021-11-23
CN2022128601 2022-10-31

Publications (1)

Publication Number Publication Date
ECSP24038829A true ECSP24038829A (es) 2024-06-28

Family

ID=84370237

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202438829A ECSP24038829A (es) 2021-11-23 2024-05-21 Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Country Status (29)

Country Link
US (2) US12084442B2 (es)
EP (2) EP4656240A1 (es)
JP (1) JP7826477B2 (es)
KR (1) KR20240110040A (es)
CN (1) CN118382623A (es)
AR (1) AR127698A1 (es)
AU (1) AU2022396087A1 (es)
CA (1) CA3235682A1 (es)
CL (1) CL2024001524A1 (es)
CO (1) CO2024006398A2 (es)
CR (1) CR20240216A (es)
DK (1) DK4436662T3 (es)
DO (1) DOP2024000096A (es)
EC (1) ECSP24038829A (es)
ES (1) ES3054973T3 (es)
FI (1) FI4436662T3 (es)
HR (1) HRP20251558T1 (es)
IL (1) IL312689A (es)
JO (1) JOP20240119A1 (es)
LT (1) LT4436662T (es)
MA (1) MA67325B1 (es)
MX (1) MX2024006176A (es)
PE (1) PE20241328A1 (es)
PL (1) PL4436662T3 (es)
PT (1) PT4436662T (es)
RS (1) RS67492B9 (es)
TW (1) TW202329949A (es)
UY (1) UY40025A (es)
WO (1) WO2023094965A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260015867A (ko) * 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6521607B1 (en) 1999-09-23 2003-02-18 Pharmacia Corporation (R)-chiral halogenated substituted N-phenoxy N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
IL152081A0 (en) 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1537114B8 (en) 2002-08-07 2007-10-03 Novartis AG Organic compounds as agents for the treatment of aldosterone mediated conditions
WO2004046145A1 (en) 2002-11-18 2004-06-03 Novartis Ag Imidazo[1, 5a]pyridine derivatives and methods for treating aldosterone mediated diseases
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
AR050251A1 (es) 2004-05-28 2006-10-11 Speedel Experimenta Ag Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto
CA2568159A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors
CN1997643A (zh) 2004-05-28 2007-07-11 斯皮德尔实验股份公司 杂环化合物及其作为醛固酮合酶抑制剂的应用
TW200611897A (en) 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
EP2009080A4 (en) 2006-04-04 2010-05-26 Taiyo Nippon Sanso Corp METHOD OF REMOVING METHANE, METHANE PARATOR AND METHOD USE SYSTEM
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
JP2010501573A (ja) 2006-08-25 2010-01-21 ノバルティス アクチエンゲゼルシャフト アルドステロン合成酵素および／または１１−β−ヒドロキシラーゼおよび／またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体
WO2008076860A1 (en) 2006-12-18 2008-06-26 Novartis Ag 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
CN101578272A (zh) 2006-12-18 2009-11-11 诺瓦提斯公司 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途
EP2094680A2 (en) 2006-12-18 2009-09-02 Novartis AG Imidazoles as aldosterone synthase inhibitors
PL2134720T3 (pl) 2007-03-29 2011-04-29 Novartis Ag Heterocykliczne spiro-związki
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2019241311A1 (en) * 2018-06-11 2019-12-19 Northeastern University Selective ligands for modulation of girk channels
KR20230022829A (ko) 2020-03-03 2023-02-16 트웬티에잇-세븐, 인크. Rna 결합 단백질 또는 rna 변형 단백질을 표적으로 하는 화합물
WO2022074567A1 (en) 2020-10-06 2022-04-14 Novartis Ag Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia

Also Published As

Publication number Publication date
MA67325B1 (fr) 2025-11-28
EP4436662A1 (en) 2024-10-02
PT4436662T (pt) 2025-12-16
US20250214989A1 (en) 2025-07-03
ES3054973T3 (en) 2026-02-09
PE20241328A1 (es) 2024-06-26
CR20240216A (es) 2024-07-01
JOP20240119A1 (ar) 2024-05-23
CL2024001524A1 (es) 2024-11-08
EP4436662B1 (en) 2025-09-17
JP2024543107A (ja) 2024-11-19
US20230203032A1 (en) 2023-06-29
CN118382623A (zh) 2024-07-23
UY40025A (es) 2023-06-15
KR20240110040A (ko) 2024-07-12
TW202329949A (zh) 2023-08-01
FI4436662T3 (fi) 2025-12-12
US12084442B2 (en) 2024-09-10
RS67492B1 (sr) 2025-12-31
IL312689A (en) 2024-07-01
MX2024006176A (es) 2024-06-11
CO2024006398A2 (es) 2024-07-18
EP4656240A1 (en) 2025-12-03
DK4436662T3 (da) 2025-12-22
DOP2024000096A (es) 2024-06-30
RS67492B9 (sr) 2026-02-27
HRP20251558T1 (hr) 2026-01-16
CA3235682A1 (en) 2023-06-01
JP7826477B2 (ja) 2026-03-09
AR127698A1 (es) 2024-02-21
PL4436662T3 (pl) 2026-02-16
LT4436662T (lt) 2025-12-29
AU2022396087A1 (en) 2024-04-11
WO2023094965A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
CO2022008091A2 (es) Inhibidores de kras g12c
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
UY38057A (es) Inhibidores de sarcómero cardíaco
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
CO2020014677A2 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2025011377A2 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
PY2018921A (es) Agentes antiproliferativos para el tratamiento de pah
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
EA202192760A1 (ru) Трициклические соединения
ECSP24038829A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
CU24543B1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
MX2020008706A (es) Nuevos compuestos de opioides y sus usos.
CO2025010725A2 (es) Compuestos moduladores de receptores de dopamina d3/d2